Partners
ITM
Expertise Partner
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a
new generation of radiomolecular precision therapeutics and diagnostics for hard-to treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners
through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life
Applied BioMath
Program Partner
Applied BioMath applies biosimulation, including quantitative systems pharmacology, PKPD, bioinformatics, machine learning, clinical pharmacology, and software solutions
to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Their
approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through all phases of clinical trials. The Applied
BioMath team leverages their expertise in biology, mathematical modeling and analysis, high-performance computing, and industr
Shine
Innovation Partner
SHINE is a next-generation nuclear technology company, focused on deploying state-of-the-art fusion technology to help solve global problems and create a scalable
path toward practical fusion energy. SHINE deploys its safe, cost-effective and
environmentally-friendly technology in a step-wise approach, beginning with our
systems used for advanced industrial imaging in non-destructive testing of components used in aerospace, defense, transportation, energy and other sectors. SHINE’s proprietary medical isotope production creates Molybdenum 99 and non-carrier added Lutetium 177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. For more information, follow SHINE on Facebook, LinkedIn and Twitter.
Trasis
Innovation Partner
Trasis was founded in 2004 by Gauthier Philippart and Jean-Luc Morelle, the designers of the first radiosynthesizers to combine high-yield synthesis and GMP. They put together their expertise and their knowledge of the radiopharmaceutical industry and founded Trasis, an innovative and forward-looking company. Trasis has now a track-record in developing instruments and methods recognized throughout the world. At Trasis we are dedicated to helping the medical community access new radiolabelled therapeutic and diagnostic substances easily and faster. To this end, we
design, manufacture, sell and support high performance synthesizers, dose preparation equipment, their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API)
and assist our customers with their regulatory affairs. Our proven radiopharmaceutical expertise, coupled with our high end instruments allow
us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.
Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies
Ionetix
Exhibition Partner
IONETIX is a full-service, end-to-end radiopharmaceutical solutions provider. Utilizing a proprietary cyclotron technology platform, Ionetix develops innovative accelerator solutions to produce medical radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals.
Ionetix is currently in the process of establishing the first commercial alpha isotope manufacturing and distribution facility dedicated to the production of Actinium-225 (Ac- 225) and Astatine-211 (At- 211). Ionetix will provide isotope production, drug manufacturing and distribution logistics for these alpha isotopes beginning in early
2023.
Macrocyclics Inc
Exhibition partner
Macrocyclics, Inc., established in 1995 and headquartered in Plano, Texas, is a Contract Development and Manufacturing Organization (CDMO) focused on the early phases of pharmaceutical products. As a subsidiary of Orano Med, a clinical stage radiopharmaceutical company pioneering 212Pb, Macrocyclics has become a key player in supplying high-quality chelating agents to the global radiopharmaceutical industry. The company operates from its facility in Plano, encompassing 20,000 sqft of wet chemistry labs equipped for bench-top and sub-pilot scale manufacturing. With the incorporation of two controlled Good Manufacturing Practice (GMP) suites and the commissioning of the Plano facility in 2016, Macrocyclics demonstrates a commitment to maintaining cutting-edge infrastructure.
PharmaLogic
Exhibition Partner
PharmaLogic is a world-class contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the
treatment of cancers and other diseases. PharmaLogic has decades of expertise in drug development from discovery to commercialization through atop-tier network of
radiopharmacies in North America. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more
information, visit:
SpectronRx
Exhibition Partner
SpectronRx is a diagnostic and therapeutic radiopharmaceutical developer and manufacturer with three distinct specialties: Radiopharmaceutical Contract Development (RCDMO), Radiopharmaceutical Contract Manufacturing (RCMO), and Isotope Production. The company performs all scales of development, from initial conjugations through scale-up and commercial distribution. It also has the capacity to run clinical trials. Additionally, SpectronRx's deep industry knowledge, technical prowess and state-of-the-art facilities enable the company to significantly condense the timeline for bringing new medicines to market, which has the dual benefit of saving lives and driving greater profitability for clients. With a large staff of radiochemists, radiopharmacists, scientists and engineers, dozens of qualified clean rooms, and over 140,000 sq. ft. of production space in Indiana, with additional facilities in Danbury, Connecticut and Europe, SpectronRx now supplies therapeutic and diagnostic radiopharmaceuticals to six continents. The company has been EMA and FDA inspected and can produce and procure any currently used radioisotopes, including actinium-225.
Northstar
Event Partner
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing therapeutic and diagnostic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services. Its proven management team and environmentally preferable, non-uranium based technologies have made it an emerging leader at the forefront of U.S. medical radioisotope and radiopharmaceutical production. NorthStar is poised to be the first commercial-scale producer of non-carrier added (n.c.a.) actinium-225 (Ac-225) and copper-67 (Cu-67). Its Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) services unit will provide customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their programs.
Radioisotope Life Sciences
Event Partner
RLS (Radioisotope Life Sciences) Inc., the nation’s only accredited nuclear pharmacy group, and the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.